documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
13,127 rows where agency_id = "FDA" and posted_year = 2023 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: open_for_comment, withdrawn, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
document_type 5
- Other 9,984
- Supporting & Related Material 2,162
- Notice 896
- Rule 56
- Proposed Rule 29
posted_year 1
- 2023 · 13,127 ✖
agency_id 1
- FDA · 13,127 ✖
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2022-E-2011-0005 | FDA | FDA-2022-E-2011 | Letter to U. S. Patent and Trademark Office from FDA CDER | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:12:16Z | 0 | 0 | 0900006486365699 | ||
| FDA-2022-E-2010-0005 | FDA | FDA-2022-E-2010 | Letter to U. S. Patent and Trademark Office from FDA CDER | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:12:02Z | 0 | 0 | 0900006486365697 | ||
| FDA-2022-E-2014-0005 | FDA | FDA-2022-E-2014 | Letter from FDA CDER to U.S. Patent and Trademark Office | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:09:57Z | 0 | 0 | 0900006486365a1a | ||
| FDA-2022-N-2226-0144 | FDA | FDA-2022-N-2226 | Tab C - FDA Salt Substitutes - NPRM and PRIA - Final to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T17:42:15Z | 0 | 0 | 0900006486366ef1 | |||
| FDA-2019-N-4750-0041 | FDA | FDA-2019-N-4750 | Memorandum to FDA DMS on Partially Hydrogenated Oils | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:56:12Z | 0 | 0 | 0900006486365e65 | |||
| FDA-2019-N-4750-0045 | FDA | FDA-2019-N-4750 | Tab A - PHOs RIA - Original to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:56:30Z | 0 | 0 | 0900006486365e69 | |||
| FDA-1997-S-0006-2049 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | Courtesy letter and related material from FDA CFSAN to Vedistry Pvt Ltd. | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T18:04:52Z | 0 | 0 | 090000648635f527 | ||
| FDA-1997-S-0006-2046 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | Courtesy letter and related material from FDA CFSAN to Wooshin Industrial Co., Ltd. | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T18:04:18Z | 0 | 0 | 090000648635f0c5 | ||
| FDA-1997-S-0006-2043 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | Courtesy letter and related material from CFSAN to Arbonne International LLC | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T18:03:49Z | 0 | 0 | 090000648635de73 | ||
| FDA-1997-S-0006-2048 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | Courtesy letter and related material from FDA CFSAN to Wooshin Industrial Co., Ltd. | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T18:04:42Z | 0 | 0 | 090000648635f525 | ||
| FDA-2023-H-5636-0001 | FDA | FDA-2023-H-5636 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:34:31Z | 0 | 0 | 0900006486361437 | ||
| FDA-2022-E-2012-0005 | FDA | FDA-2022-E-2012 | Letter to U. S. Patent and Trademark Office from FDA CDER | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:12:29Z | 0 | 0 | 090000648636569b | ||
| FDA-2019-E-3218-0005 | FDA | FDA-2019-E-3218 | Letter from FDA CDER to U.S. Patent and Trademark Office | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:03:25Z | 0 | 0 | 0900006486365a16 | ||
| FDA-2022-E-2013-0005 | FDA | FDA-2022-E-2013 | Letter to U. S. Patent and Trademark Office from FDA CDER | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:12:42Z | 0 | 0 | 0900006486365ce2 | ||
| FDA-2019-N-4750-0048 | FDA | FDA-2019-N-4750 | Tab B - PHOs PRIA - Comparison OMB Original to Final | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:56:55Z | 0 | 0 | 0900006486365e8c | |||
| FDA-2019-N-4750-0051 | FDA | FDA-2019-N-4750 | Tab C - PHOs NPRM - Final to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:57:23Z | 0 | 0 | 0900006486365e91 | |||
| FDA-2023-H-5667-0001 | FDA | FDA-2023-H-5667 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T16:57:02Z | 0 | 0 | 0900006486365657 | ||
| FDA-1997-S-0006-2044 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | Courtesy letter and related material from FDA CFSAN to CalmCo LLC | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T18:03:58Z | 0 | 0 | 090000648635d608 | ||
| FDA-2023-H-5657-0001 | FDA | FDA-2023-H-5657 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2024-01-01T05:00:00Z | 2024-01-01T19:24:51Z | 0 | 0 | 0900006486366f65 | ||
| FDA-2023-H-5410-0001 | FDA | FDA-2023-H-5410 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2024-01-01T05:00:00Z | 2024-01-01T18:58:41Z | 0 | 0 | 0900006486365c81 | ||
| FDA-2019-N-4750-0046 | FDA | FDA-2019-N-4750 | Tab B - PHOs DFR - Comparison OMB Original to Final | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:56:46Z | 0 | 0 | 0900006486365e6a | |||
| FDA-2019-N-4750-0047 | FDA | FDA-2019-N-4750 | Tab B - PHOs NPRM - Comparison OMB Original to Final | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:56:50Z | 0 | 0 | 0900006486365e6b | |||
| FDA-2019-N-4750-0050 | FDA | FDA-2019-N-4750 | Tab C - PHOs DFR - Final to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:57:18Z | 0 | 0 | 0900006486365e8e | |||
| FDA-2023-H-5663-0001 | FDA | FDA-2023-H-5663 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T16:52:49Z | 0 | 0 | 090000648636564e | ||
| FDA-2023-H-5661-0001 | FDA | FDA-2023-H-5661 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T16:39:48Z | 0 | 0 | 0900006486366919 | ||
| FDA-2023-H-5662-0001 | FDA | FDA-2023-H-5662 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T16:41:58Z | 0 | 0 | 090000648636692b | ||
| FDA-2022-N-2226-0142 | FDA | FDA-2022-N-2226 | Tab A - FDA Salt Substitutes NPRM and PRIA - Original to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T17:41:54Z | 0 | 0 | 0900006486366edd | |||
| FDA-2022-N-2226-0141 | FDA | FDA-2022-N-2226 | Memorandum to FDA DMS on Salt Substitutes NPRM | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T17:41:49Z | 0 | 0 | 0900006486366eda | |||
| FDA-2023-U-5565-0001 | FDA | FDA-2023-U-5565 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T17:07:31Z | 0 | 0 | 09000064863612e4 | ||
| FDA-2023-H-5665-0001 | FDA | FDA-2023-H-5665 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T17:15:06Z | 0 | 0 | 0900006486365654 | ||
| FDA-2023-H-5269-0001 | FDA | FDA-2023-H-5269 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T17:24:00Z | 0 | 0 | 0900006486365665 | ||
| FDA-1997-S-0006-2050 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | Courtesy letter and related material from FDA CFSAN to CalmCo LLC | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T18:05:03Z | 0 | 0 | 090000648635f529 | ||
| FDA-2019-E-5256-0005 | FDA | FDA-2019-E-5256 | Letter from FDA CDER to U.S. Patent and Trademark Office | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T13:26:57Z | 0 | 0 | 090000648636562d | ||
| FDA-2019-N-4750-0044 | FDA | FDA-2019-N-4750 | Tab A - PHOs PRIA - Original to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:56:25Z | 0 | 0 | 0900006486365e68 | |||
| FDA-2019-N-4750-0049 | FDA | FDA-2019-N-4750 | Tab B - PHOs RIA - Comparison OMB Original to Final | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:57:01Z | 0 | 0 | 0900006486365e8d | |||
| FDA-2019-N-4750-0053 | FDA | FDA-2019-N-4750 | Tab C - PHOs RIA - Final to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:57:32Z | 0 | 0 | 0900006486365e93 | |||
| FDA-2023-H-5666-0001 | FDA | FDA-2023-H-5666 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T16:46:57Z | 0 | 0 | 0900006486364c23 | ||
| FDA-2023-H-5660-0001 | FDA | FDA-2023-H-5660 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T16:38:09Z | 0 | 0 | 09000064863665e4 | ||
| FDA-2023-H-5672-0001 | FDA | FDA-2023-H-5672 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T17:28:45Z | 0 | 0 | 0900006486365662 | ||
| FDA-2019-E-3017-0005 | FDA | FDA-2019-E-3017 | Letter to U. S. Patent and Trademark Office from FDA CDER | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:13:37Z | 0 | 0 | 09000064863656c8 | ||
| FDA-2022-E-2016-0005 | FDA | FDA-2022-E-2016 | Letter from FDA CDER to U.S. Patent and Trademark Office | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:10:40Z | 0 | 0 | 0900006486365692 | ||
| FDA-2019-E-3287-0005 | FDA | FDA-2019-E-3287 | Letter from FDA CDER to U.S. Patent and Trademark Office | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:14:00Z | 0 | 0 | 0900006486365c60 | ||
| FDA-2023-H-5673-0001 | FDA | FDA-2023-H-5673 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T15:05:01Z | 0 | 0 | 090000648636568b | ||
| FDA-2023-H-5674-0001 | FDA | FDA-2023-H-5674 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T15:08:02Z | 0 | 0 | 0900006486365c7b | ||
| FDA-2023-H-5603-0001 | FDA | FDA-2023-H-5603 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:34:53Z | 0 | 0 | 0900006486365669 | ||
| FDA-2019-N-4750-0052 | FDA | FDA-2019-N-4750 | Tab C - PHOs PRIA - Final to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:57:27Z | 0 | 0 | 0900006486365e92 | |||
| FDA-2023-H-5177-0001 | FDA | FDA-2023-H-5177 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-01T05:00:00Z | 2023-12-01T15:00:37Z | 0 | 0 | 09000064862c07f3 | ||
| FDA-2023-H-5658-0001 | FDA | FDA-2023-H-5658 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2024-01-02T05:00:00Z | 2024-01-02T13:25:31Z | 0 | 0 | 0900006486366f68 | ||
| FDA-2022-N-2226-0143 | FDA | FDA-2022-N-2226 | Tab B - FDA Salt Substitutes NPRM and PRIA - Comparison OMB Original to Final | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T17:42:10Z | 0 | 0 | 0900006486366ee2 | |||
| FDA-1997-S-0006-2045 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | Courtesy letter and related material from FDA CFSAN to Robinson Pharma | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T18:04:07Z | 0 | 0 | 090000648635f0c2 | ||
| FDA-1997-S-0006-2047 | FDA | Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 | Courtesy letter and related material from FDA CFSAN to Wooshin Industrial Co., Ltd. | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T18:04:30Z | 0 | 0 | 090000648635f521 | ||
| FDA-2023-H-5664-0001 | FDA | FDA-2023-H-5664 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T17:02:17Z | 0 | 0 | 0900006486365651 | ||
| FDA-2023-H-5670-0001 | FDA | FDA-2023-H-5670 | Complaint | Other | Complaint | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T16:51:21Z | 0 | 0 | 0900006486366931 | ||
| FDA-2019-N-4750-0042 | FDA | FDA-2019-N-4750 | Tab A - PHOs DFR - Original to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:56:16Z | 0 | 0 | 0900006486365e66 | |||
| FDA-2022-E-2009-0005 | FDA | FDA-2022-E-2009 | Letter to U. S. Patent and Trademark Office from FDA CDER | Other | Letter(s) | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T05:00:00Z | 2023-12-29T14:11:49Z | 0 | 0 | 0900006486365c63 | ||
| FDA-2019-N-4750-0043 | FDA | FDA-2019-N-4750 | Tab A - PHOs NPRM - Original to OMB | Supporting & Related Material | Background Material | 2023-12-29T05:00:00Z | 2023 | 12 | 2023-12-29T16:56:21Z | 0 | 0 | 0900006486365e67 | |||
| FDA-2023-H-5639-0001 | FDA | FDA-2023-H-5639 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T15:19:51Z | 0 | 0 | 090000648635d710 | ||
| FDA-2023-H-5650-0001 | FDA | FDA-2023-H-5650 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T17:50:58Z | 0 | 0 | 0900006486361319 | ||
| FDA-2023-D-5408-0002 | FDA | FDA-2023-D-5408 | Reformulating Drug Products That Contain Carbomers Manufactured With Benzene; Guidance for Industry - Final Guidance | Other | Guidance | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2024-11-12T06:24:20Z | 1 | 0 | 090000648635c332 | ||
| FDA-2021-N-0039-0002 | FDA | FDA-2021-N-0039 | Electronic Submissions; Update to the Specifications for Preparing and Submitting Postmarket Individual Case Safety Reports for Vaccines; Technical Specification | Notice | Notice of Availability | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2024-11-12T06:21:06Z | 2023-28594 | 1 | 0 | 090000648636182b | |
| FDA-2023-H-5647-0001 | FDA | FDA-2023-H-5647 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T18:23:02Z | 0 | 0 | 0900006486361407 | ||
| FDA-2023-H-5648-0001 | FDA | FDA-2023-H-5648 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T18:26:47Z | 0 | 0 | 090000648636140a | ||
| FDA-2023-H-5643-0001 | FDA | FDA-2023-H-5643 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T17:54:09Z | 0 | 0 | 09000064863612e1 | ||
| FDA-2023-H-5645-0001 | FDA | FDA-2023-H-5645 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T21:03:53Z | 0 | 0 | 0900006486364790 | ||
| FDA-2023-D-4177-0021 | FDA | FDA-2023-D-4177 | Quality Considerations for Topical Ophthalmic Drug Products; Revised Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T15:10:09Z | 2023-28595 | 0 | 0 | 090000648636165b | |
| FDA-2023-D-4299-0002 | FDA | FDA-2023-D-4299 | Potency Assurance for Cellular and Gene Therapy Products; Draft Guidance for Industry | Other | Guidance | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2024-03-28T03:59:59Z | 2024-11-12T06:25:10Z | 1 | 0 | 0900006486364261 | |
| FDA-2023-H-5637-0001 | FDA | FDA-2023-H-5637 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2024-01-01T05:00:00Z | 2024-01-01T19:25:25Z | 0 | 0 | 09000064863647c6 | ||
| FDA-2020-Q-1295-0026 | FDA | FDA-2020-Q-1295 | Withdrawal request for docket number FDA-2020-Q-1295 | Other | Withdrawal | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T18:40:58Z | 0 | 0 | 0900006486364403 | ||
| FDA-2020-Q-1295-0027 | FDA | FDA-2020-Q-1295 | FDA response to a withdrawal request for CA and Migraine Final | Other | Acknowledgement Letter/Receipt | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T18:41:04Z | 0 | 0 | 0900006486364405 | ||
| FDA-2023-D-4177-0022 | FDA | FDA-2023-D-4177 | Quality Considerations for Topical Ophthalmic Drug Products; Guidance for Industry; Draft Guidance | Other | Guidance | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2024-02-27T04:59:59Z | 2025-02-04T02:01:06Z | 1 | 0 | 09000064863613f7 | |
| FDA-2023-H-5644-0001 | FDA | FDA-2023-H-5644 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T18:27:41Z | 0 | 0 | 09000064863612e7 | ||
| FDA-2023-H-5642-0001 | FDA | FDA-2023-H-5642 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T17:43:17Z | 0 | 0 | 09000064863612d4 | ||
| FDA-2023-H-5641-0001 | FDA | FDA-2023-H-5641 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T17:05:25Z | 0 | 0 | 09000064863612d1 | ||
| FDA-2023-D-4299-0001 | FDA | FDA-2023-D-4299 | Potency Assurance for Cellular and Gene Therapy Products; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T16:34:21Z | 2023-28596 | 0 | 0 | 090000648636182c | |
| FDA-2023-H-5646-0001 | FDA | FDA-2023-H-5646 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T18:18:16Z | 0 | 0 | 0900006486361404 | ||
| FDA-2023-H-5640-0001 | FDA | FDA-2023-H-5640 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T16:52:22Z | 0 | 0 | 09000064863612ce | ||
| FDA-2023-D-5408-0001 | FDA | FDA-2023-D-5408 | Reformulating Drug Products That Contain Carbomers Manufactured With Benzene; Guidance for Industry; Availability | Notice | Notice of Availability | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T16:02:50Z | 2023-28675 | 0 | 0 | 090000648636165e | |
| FDA-2021-V-0192-0007 | FDA | FDA-2021-V-0192 | Variance Amendment Report from Digital Projection Inc. /Delta Electronics Inc. | Other | Amendment | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T12:46:02Z | 0 | 0 | 090000648635cf0d | ||
| FDA-2023-H-5413-0001 | FDA | FDA-2023-H-5413 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T20:40:47Z | 0 | 0 | 09000064863647ec | ||
| FDA-2023-H-5638-0001 | FDA | FDA-2023-H-5638 | Complaint | Other | Complaint | 2023-12-28T05:00:00Z | 2023 | 12 | 2023-12-28T05:00:00Z | 2023-12-28T20:11:28Z | 0 | 0 | 09000064863647e6 | ||
| FDA-2022-E-0931-0005 | FDA | FDA-2022-E-0931 | Determination of Regulatory Review Period for Purposes of Patent Extension; ZOKINVY | Notice | Determinations | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2024-06-25T03:59:59Z | 2024-06-25T01:00:33Z | 2023-28511 | 0 | 0 | 090000648635c4ea |
| FDA-2023-V-5683-0002 | FDA | FDA-2023-V-5683 | Acknowledgment Letter from FDA DMS to Billy Stone | Other | Acknowledgement Letter/Receipt | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T16:25:25Z | 0 | 0 | 090000648635a86a | ||
| FDA-2023-V-5683-0001 | FDA | FDA-2023-V-5683 | Variance Application from Billy Stone | Other | Application for Variance (VAR) | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T16:22:49Z | 0 | 0 | 090000648635a867 | ||
| FDA-2023-V-5681-0002 | FDA | FDA-2023-V-5681 | Acknowledgment Letter from FDA DMS to Kasey Lelito | Other | Acknowledgement Letter/Receipt | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T16:12:46Z | 0 | 0 | 090000648635a7e7 | ||
| FDA-2023-H-5602-0001 | FDA | FDA-2023-H-5602 | Complaint | Other | Complaint | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T18:32:44Z | 0 | 0 | 090000648635cbcd | ||
| FDA-2023-H-5627-0001 | FDA | FDA-2023-H-5627 | Complaint | Other | Complaint | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T23:46:41Z | 0 | 0 | 090000648635d348 | ||
| FDA-2023-H-5624-0001 | FDA | FDA-2023-H-5624 | Complaint | Other | Complaint | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T21:46:25Z | 0 | 0 | 090000648635ce56 | ||
| FDA-2023-V-5190-0003 | FDA | FDA-2023-V-5190 | Variance Approval Letter from FDA CDRH to ACT Entertainment | Other | Approval for Variance (VRA) | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T13:52:27Z | 0 | 0 | 090000648635a687 | ||
| FDA-2023-V-5680-0002 | FDA | FDA-2023-V-5680 | Acknowledgment Letter from FDA DMS to Pitchblend Agency Inc. | Other | Acknowledgement Letter/Receipt | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T16:04:59Z | 0 | 0 | 090000648635a7ae | ||
| FDA-2023-V-5681-0001 | FDA | FDA-2023-V-5681 | Variance Application from Kasey Lelito | Other | Application for Variance (VAR) | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T16:08:43Z | 0 | 0 | 090000648635a9d3 | ||
| FDA-2009-N-0582-0130 | FDA | FDA-2009-N-0582 | Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule: Questions and Answers; Guidance for Industry; Small Entity Compliance Guide; Availability | Rule | Final Rule with Request for Comments | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T14:34:36Z | 2023-28530 | 0 | 0 | 090000648635c371 | |
| FDA-2023-H-5625-0001 | FDA | FDA-2023-H-5625 | Complaint | Other | Complaint | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T21:34:21Z | 0 | 0 | 090000648635d678 | ||
| FDA-2023-V-5676-0001 | FDA | FDA-2023-V-5676 | Variance Application from Doug Carmean | Other | Application for Variance (VAR) | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T14:03:42Z | 0 | 0 | 090000648635a648 | ||
| FDA-2023-V-5686-0002 | FDA | FDA-2023-V-5686 | Acknowledgment Letter from FDA DMS to Will Wall | Other | Acknowledgement Letter/Receipt | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T16:37:19Z | 0 | 0 | 090000648635a8bf | ||
| FDA-2023-H-5618-0001 | FDA | FDA-2023-H-5618 | Complaint | Other | Complaint | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T18:07:32Z | 0 | 0 | 090000648635c85f | ||
| FDA-2023-H-5626-0001 | FDA | FDA-2023-H-5626 | Complaint | Other | Complaint | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T23:44:12Z | 0 | 0 | 090000648635d67e | ||
| FDA-2023-F-5500-0001 | FDA | FDA-2023-F-5500 | Kemin Industries, Inc.; Filing of Food Additive Petition (Animal Use); Chromium Propionate; Correction. | Notice | Correction | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-29T15:38:50Z | 2023-28512 | 0 | 0 | 090000648635c3a9 | |
| FDA-2023-F-2415-0004 | FDA | FDA-2023-F-2415 | Kemin Industries, Inc.; Filing of Food Additive Petition (Animal Use); Chromium Propionate; Correction. | Notice | Correction | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-29T15:48:26Z | 2023-28512 | 0 | 0 | 090000648635d693 | |
| FDA-2023-P-5687-0001 | FDA | FDA-2023-P-5687 | Citizen Petition from Bionpharma, Inc. | Other | Citizen Petition | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2025-03-13T18:36:06Z | 0 | 0 | 090000648635b114 | ||
| FDA-2023-F-5500-0002 | FDA | FDA-2023-F-5500 | Environmental Assessment Phase 1) Chromium Propionate in Turkey Diets | Supporting & Related Material | Background Material | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T22:00:20Z | 0 | 0 | 090000648635d692 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);